Co-Diagnostics (NASDAQ:CODX – Get Free Report) and Compugen (NASDAQ:CGEN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.
Profitability
This table compares Co-Diagnostics and Compugen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Co-Diagnostics | -6,531.77% | -210.99% | -174.97% |
| Compugen | 47.56% | 42.57% | 26.13% |
Insider & Institutional Ownership
15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 9.5% of Compugen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Co-Diagnostics and Compugen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Co-Diagnostics | $620,000.00 | 7.36 | -$46.90 million | ($10.32) | -0.06 |
| Compugen | $72.76 million | 2.55 | $35.34 million | $0.38 | 5.16 |
Compugen has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Co-Diagnostics and Compugen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Co-Diagnostics | 1 | 1 | 1 | 1 | 2.50 |
| Compugen | 0 | 1 | 3 | 1 | 3.00 |
Co-Diagnostics presently has a consensus target price of $67.50, suggesting a potential upside of 10,221.10%. Compugen has a consensus target price of $5.00, suggesting a potential upside of 155.10%. Given Co-Diagnostics’ higher probable upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Compugen.
Risk and Volatility
Co-Diagnostics has a beta of 2.9, meaning that its stock price is 190% more volatile than the S&P 500. Comparatively, Compugen has a beta of 2.78, meaning that its stock price is 178% more volatile than the S&P 500.
Summary
Compugen beats Co-Diagnostics on 10 of the 14 factors compared between the two stocks.
About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company’s immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
